Article Text
Abstract
Since the 1990s, glycated haemoglobin (HbA1C) has been the gold standard for monitoring glycaemic control in people diagnosed as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Discussions are underway about diagnosing diabetes mellitus on the basis of HbA1C titres and using HbA1C tests to screen for T2DM. These discussions have focused on the relative benefits for individual patients, with some attention directed towards reduced costs to healthcare systems and benefits to society. We argue that there are strong ethical reasons for adopting HbA1C-based diagnosis and T2DM screening that have not yet been articulated. The rationale includes the differential impact of HbA1C-based diabetic testing on disadvantaged groups, and what we are beginning to learn about HbA1C vis-à-vis population health. Although it is arguable that screening must primarily benefit the individual, using HbA1C to diagnose and screen for T2DM may promote a more just distribution of health resources and lead to advances in investigating, monitoring and tackling the social determinants of health.
- Animal experimentation
- public health ethics
- applied and professional ethics
- philosophy of medicine
- social control of science/technology
- evidence-based medicine
- trust and Dr-patient relationship
- public health
- primary care and general practice
- feminist ethics
Statistics from Altmetric.com
Footnotes
Funding CD is funded through support from Alberta Innovates—Health Solutions Establishment and Incentive Grants (AI-HS to MR) and a University of Calgary Veterinary Medicine Postdoctoral Entrance Award. MR holds a Population Health Investigator award from Alberta Innovates—Health Solutions, which is funded by the Alberta Heritage Foundation for Medical Research Endowment. She also holds a New Investigator in Societal and Cultural Dimensions of Health Award from the Canadian Institutes for Health Research. WAR received no support from external funding for her contribution to this paper.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Linked Articles
- The concise argument
Read the full text or download the PDF:
Other content recommended for you
- Should glycated haemoglobin (HbA1c) be used to detect people with type 2 diabetes mellitus and impaired glucose regulation?
- Self-administered oral glucose tolerance test with capillary glucose measurements for the screening of diabetes mellitus in high-risk adults: a feasibility study
- Performance and costs of multiple screening strategies for type 2 diabetes: two population-based studies in Shanghai, China
- Prediction of type 2 diabetes mellitus using fasting plasma glucose and HbA1c levels among individuals with impaired fasting plasma glucose: a cross-sectional study in Thailand
- Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations
- Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: a population-based survey from Pakistan
- Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol
- Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes
- Association between obesity indices and type 2 diabetes mellitus among middle-aged and elderly people in Jinan, China: a cross-sectional study
- Glycated haemoglobin A1c (HbA1c) for detection of diabetes mellitus and impaired fasting glucose in Malawi: a diagnostic accuracy study